European Heart Journal Advance Access originally published online on July 9, 2009
European Heart Journal 2009 30(21):2614-2621; doi:10.1093/eurheartj/ehp278
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention
1 Department of Cardiology, Area del Corazón, Hospital Universitario Central de Asturias, C/Julián Clavería s/n, 33006 Oviedo, Spain
2 Department of Endocrinology, Area del Corazón, Hospital Universitario Central de Asturias, C/Julián Clavería s/n, 33006 Oviedo, Spain
3 Department of Biochemistry, Area del Corazón, Hospital Universitario Central de Asturias, C/Julián Clavería s/n, 33006 Oviedo, Spain
Received 25 July 2008; revised 27 March 2009; accepted 11 June 2009; online publish-ahead-of-print 9 July 2009.
* Corresponding author. Tel: +34 985 10 94 17, Fax: +34 985 27 46 88, Email: jesusdelahera{at}gmail.com
Aims: The beneficial effect of specific measures in patients with newly detected diabetes during percutaneous coronary intervention (PCI) has been poorly studied. Here, we determined the prevalence of newly detected diabetes in a cohort of patients who underwent PCI and analysed their clinical outcome.
Methods and results: A prospective study included patients without previous diagnosis of diabetes that were referred for PCI between November 2005 and May 2006. Major cardiac events were registered after admission and during 12 months of follow-up, and oral glucose tolerance was tested at 15 days after hospital discharge. Six hundred and sixty-two consecutive patients were referred to our hospital for PCI. The distribution of the glycometabolic state of the entire population was (95% CI): known diabetes 28.8% (25.2–32.6), newly detected diabetes 16.2% (13.1–19.8), impaired glucose tolerance 24.5% (20.8–28.5), impaired fasting glucose 1% (0.4–2.4), and normal glucose regulation 29.5% (25.5–33.7). In a multivariable analysis, the presence of newly detected diabetes was not an independent predictor of cardiac events after 1 year of follow-up.
Conclusion: The prevalence of diabetes in patients who underwent PCI was very high (45%), 35% of which was patients with newly detected diabetes. In our series newly detected diabetes was not an independent predictor of outcome at 12 months. Nevertheless, this finding requires independent confirmation in other series to draw general conclusions on the whole spectrum of percutaneous interventions.
Key Words: Diabetes mellitus • Impaired glucose regulation • Oral glucose tolerance test • Coronary angioplasty